The line between 'antibacterial' and 'proven antibacterial' has just been redrawn. In August 2026, the group standard T/CIAA 008—2026 for antimicrobial sanitary pads, pantyliners and period pants was officially released, replacing the 2020 edition. The most significant change is the introduction of a 'long-lasting antimicrobial' definition, requiring efficacy after simulated use. This shift signals that simple claims based on adding antimicrobial agents will no longer suffice.
Event Background
The standard is managed by the Zhongguancun HuiZhi Antimicrobial New Material Industry Technology Innovation Alliance, with drafting units including Henan Shulai, Guangdong Institute of Microbiology, SGS, and Jinda Nano Technology. The involvement of raw material suppliers, testing bodies, and manufacturers indicates an effort to align the entire supply chain. Notably, this revision aligns with the mandatory national standard GB 15979-2024, creating a cohesive regulatory framework.
In terms of definitions, the standard now covers 'antimicrobial sanitary pads, pantyliners and period pants' instead of just 'bacteriostatic pads'. A new term, 'long-lasting antimicrobial', has been added, defined by a test where bovine serum albumin is applied to the skin-contact layer and maintained at (36±1)°C for at least 8 hours to simulate real use. This addresses a known gap: many products pass lab tests but fail under actual conditions involving sweat and secretions.
Industry Impact
For raw material suppliers, the focus shifts from mere efficacy to durability. Antimicrobial agents must now demonstrate sustained release and biocompatibility, prompting reevaluation of materials like nano-silver, chitosan, and quaternary ammonium compounds. Manufacturers will need to adjust production processes, particularly surface treatment and finishing, to ensure stable activity in simulated body fluids. This raises R&D and testing costs, potentially squeezing smaller players out of the antibacterial segment.
Testing laboratories face longer turnaround times and higher costs due to the new long-lasting efficacy protocol and alignment with GB 15979-2024. Brands will likely prefer suppliers with robust quality systems, accelerating industry consolidation. For exporters, compliance with this standard could become a competitive advantage if recognized by overseas buyers, though differences with international test methods may increase compliance burdens.